Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 55 min ago
Peer-reviewedCC BYJournal for ImmunoTherapy of Cancer

644 Combining radiopharmaceutical ligand therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment

  • Shuai Yang1
  • Tanya Dorff2
  • Jiangyue Liu3
  • Yukiko Yamaguchi4
  • Yuwei Ren5
  • Pauline Jeanjean6
  • Kofi Poku7
  • Reginaldo Rosa8
  • Cari Young9
  • Lea Christian7
  • Iveta Fajnorova10
  • Christine Mona10
13 more authors
  • Saul J Priceman11
  • John P Murad12
  • Yu-Hsuan Fu13
  • Lupita S Lopez5
  • Ines Azrour14
  • Ava Fakharpour14
  • Laura H Porter15
  • Vikram Adhikarla13
  • Russell C Rockne13
  • Stephen J Forman13
  • Yun Rose Li13
  • Gail P Risbridger16
  • Renea Taylor16
16 affiliations
  1. 1Department of Epidemiology and Biostatistics, Mel & Enid Zuckerman College of Public Health, University of Arizona, Tucson, Arizona, USA
  2. 2Department of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, Duarte, California, USA
  3. 31University of Southern California, Los Angeles, CA, USA
  4. 42 Department of Medicine, University of Southern California Keck School of Medicine, Los Angeles, California, USA
  5. 5Keck School of Medicine of USC, Los Angeles, CA, USA
  6. 62Memorial Sloan Kettering Cancer Center, New York, NY, USA
  7. 73Beckman Research Institute of City of Hope, Duarte, CA, USA
  8. 82Keck School of Medicine of USC, Los Angeles, CA, USA
  9. 9Beckman Research Institute of City of Hope, Duarte, CA, USA
  10. 104David Geffen School of Medicine of UCLA, Los Angeles, CA, USA
  11. 11Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
  12. 12Keck Medicine of University of Southern California, Los Angeles, CA, USA
  13. 13City of Hope, Duarte, CA, USA
  14. 14UCLA, Los Angeles, CA, USA
  15. 15Monash Biomedicine Discovery Institute, Clayton, VIC, Australia
  16. 16Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
Open at sourcePDFDOICite

Related

  1. Optimized dosing of spatially heterogeneous radiopharmaceutical therapy reprograms poorly immunogenic tumors to enhance response to immune checkpoint blockade
    M. E. Takashima, Z. Danaceau, M. Bio Idrissou +13
    bioRxivPreprintAll rights reservedFull textOncologybioRxivPMC
  2. Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.
    Qiaoyan Qu, Jintan Xiao, Bingjian Zhao +1
    Neoplasia (New York, N.Y.)Peer-reviewedCC BY-NC-NDFull textOncologyEurope PMC
  3. Radiation-Induced Remodeling of Bone Metastases and the Bone Marrow Microenvironment: From External-Beam Radiotherapy to Radiopharmaceutical Therapy
    Satoru Monzen, Akihito Kotani, Masaki Tatara +4
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  4. Targeting the Tumor Microenvironment Network to Overcome Immunotherapy Resistance in Non‐Small Cell Lung Cancer: Mechanisms to Clinical Translation
    Zengrui Wang, Zhuang Luo, Le Wang +3
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. CNS localization drives a profoundly immunosuppressive microenvironment in B‑cell lymphoma
    Jenni Niemi, Oscar Badillo-Godinez, Mats Hellström
    Scientific ReportsPeer-reviewedCC BY 4.0Full textNeurologyCrossref

Cite

BibTeXRIS
BibTeX
@article{yang2026combining,
  title = {{644 Combining radiopharmaceutical ligand therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment}},
  author = {Shuai Yang and Tanya Dorff and Jiangyue Liu and Yukiko Yamaguchi and Yuwei Ren and Pauline Jeanjean and Kofi Poku and Reginaldo Rosa and Cari Young and Lea Christian and Iveta Fajnorova and Christine Mona and Saul J Priceman and John P Murad and Yu-Hsuan Fu and Lupita S Lopez and Ines Azrour and Ava Fakharpour and Laura H Porter and Vikram Adhikarla and Russell C Rockne and Stephen J Forman and Yun Rose Li and Gail P Risbridger and Renea Taylor},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  month = nov,
  doi = {10.1136/jitc-2026-sitc2026.0644},
  url = {https://doi.org/10.1136/jitc-2026-sitc2026.0644},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - 644 Combining radiopharmaceutical ligand therapy with CAR T cells to overcome the heterogeneous immunosuppressive prostate tumor microenvironment
AU  - Shuai Yang
AU  - Tanya Dorff
AU  - Jiangyue Liu
AU  - Yukiko Yamaguchi
AU  - Yuwei Ren
AU  - Pauline Jeanjean
AU  - Kofi Poku
AU  - Reginaldo Rosa
AU  - Cari Young
AU  - Lea Christian
AU  - Iveta Fajnorova
AU  - Christine Mona
AU  - Saul J Priceman
AU  - John P Murad
AU  - Yu-Hsuan Fu
AU  - Lupita S Lopez
AU  - Ines Azrour
AU  - Ava Fakharpour
AU  - Laura H Porter
AU  - Vikram Adhikarla
AU  - Russell C Rockne
AU  - Stephen J Forman
AU  - Yun Rose Li
AU  - Gail P Risbridger
AU  - Renea Taylor
PY  - 2026
DA  - 2026/11/05
JO  - Journal for ImmunoTherapy of Cancer
DO  - 10.1136/jitc-2026-sitc2026.0644
UR  - https://doi.org/10.1136/jitc-2026-sitc2026.0644
SN  - 2051-1426
ER  -